
Cardiólogo. Subdirector médico @HUVV_SAS CIBERCV. Secretario SAC. Tutor residentes. Comisión Nacional Cardiología
- Tweets5K
- Following978
- Followers1.2K
- Likes3.1K

ALT Chart titled "The ASAP-TOO Trial: LAAC vs Non-OAC Therapy in Anticoagulation-Ineligible AF." The image shows a flowchart with three main sections. The left section illustrates high-risk AF population details and includes heart anatomy. The center section outlines the randomized ASAP-TOO trial design, highlighting the WATCHMAN 2.5 Device, and lists enrollment numbers and clinical outcomes followed up to five years. The right section displays a summary of 5-year outcomes, including primary effectiveness, safety, stroke severity, and other outcomes with percentage and quantitative data. The chart footer includes citation information for the study.

ALT Three graphs showing Kaplan–Meier estimates for prespecified events as adjudicated by the clinical-events committee at 3 years. Panel A shows freedom from death from any cause or hospitalization for heart failure (second coprimary end point), Panel B survival, and Panel C freedom from hospitalization for heart failure.

ALT A figure from the Original Article "Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients." The trial name, A-CLOSE, is in parentheses after the title. The figure shows the Kaplan–Meier estimates of the cumulative incidence of net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding events (the primary end point). The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.































